Survey of effect of topical herbal medicine (neurohelp) on the treatment of diabetic neuropathy

Survey of effect of topical herbal medicine (neurohelp) on the treatment of diabetic neuropathy: a Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170422033566N2

Enrollment

Registered

2018-06-25

Start date

2018-04-19

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic neuropathy.

Interventions

Intervention 1: Intervention group: Standard treatment (Gabapentin and Vitamins) + liquid synthetic neurohelp. Intervention 2: Control group: Standard treatment (Gabapentin and Vitamins) + Placebo.

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes with uncontrolled blood sugar diabetic peripheral neuropathy aged between 30-70 years

Exclusion criteria

Exclusion criteria: Drug and alcohol users Other reasons for the development of neuropathy, liver and kidney failure Disruption of sodium, potassium, calcium electrolytes Pregnancy or breastfeeding Wound or foot infections Lack of full awareness of patient

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: Visual Analogue Scale (VAS).;FBS. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: by glucose oxidase method.;2HPR. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: by glucose oxidase method.;B/S4PM. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: by glucose oxidase method.;Tingling. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: Visual Analogue Scale (VAS).;Numb. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: Visual Analogue Scale (VAS).	—

Measure

Time frame

Pain. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: Visual Analogue Scale (VAS).;FBS. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: by glucose oxidase method.;2HPR. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: by glucose oxidase method.;B/S4PM. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: by glucose oxidase method.;Tingling. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: Visual Analogue Scale (VAS).;Numb. Timepoint: At the beginning of the study, 2 weeks after the start of the study, 2 months and 3 months after the start of the study. Method of measurement: Visual Analogue Scale (VAS).

—

Secondary

Measure	Time frame
HbA1C. Timepoint: Start the study, three months after the intervention. Method of measurement: Blood glucose testing will be done using the Pars Test Kit and the HbA1C Assay with Diaz Kit with the diory 1200 automatic device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOurman Nezami Narjabad

Gorgan University of Medical Sciences

f.mehravar@goums.ac.ir+98 17 3243 0310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026